2011
Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial
Stone G, Witzenbichler B, Guagliumi G, Peruga J, Brodie B, Dudek D, Kornowski R, Hartmann F, Gersh B, Pocock S, Dangas G, Wong S, Fahy M, Parise H, Mehran R, Investigators O. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. The Lancet 2011, 377: 2193-2204. PMID: 21665265, DOI: 10.1016/s0140-6736(11)60764-2.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, BalloonCombined Modality TherapyConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationDrug-Eluting StentsElectrocardiographyFemaleFollow-Up StudiesHeparinHirudinsHumansKaplan-Meier EstimateMaleMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecombinant ProteinsStentsSurvival AnalysisTime FactorsTreatment OutcomeConceptsST-segment elevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionIIb/IIIa inhibitorsPercutaneous coronary interventionPaclitaxel-eluting stentsBare metal stentsBivalirudin monotherapyStent thrombosisCoronary interventionMyocardial infarctionIschaemia-driven target lesion revascularisationIschaemia-driven target vessel revascularisationMajor adverse cardiovascular eventsComposite adverse eventsHORIZONS-AMI trialPaclitaxel-eluting stentingTarget vessel revascularisationAdverse cardiovascular eventsBypass graft surgeryTarget lesion revascularisationElevation myocardial infarctionOnset of symptomsKaplan-Meier estimatesAcute myocardial infarction
2009
Role of Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty Results From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Dangas G, Mehran R, Guagliumi G, Caixeta A, Witzenbichler B, Aoki J, Peruga J, Brodie B, Dudek D, Kornowski R, Rabbani L, Parise H, Stone G, Investigators H. Role of Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty Results From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. Journal Of The American College Of Cardiology 2009, 54: 1438-1446. PMID: 19796737, DOI: 10.1016/j.jacc.2009.06.021.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAngioplasty, BalloonAnticoagulantsClopidogrelConfidence IntervalsFemaleHirudinsHumansLogistic ModelsMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsProportional Hazards ModelsRecombinant ProteinsTiclopidineTreatment OutcomeConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionPrimary PCIGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsClopidogrel loading doseHORIZONS-AMI trialElevation myocardial infarctionLoading doseMyocardial infarctionAdverse cardiac event ratesMajor adverse cardiac eventsEvent ratesCardiac event rateLoading dose groupProbable stent thrombosisAdverse cardiac eventsAdverse event ratesPercutaneous coronary interventionHigher bleeding rateBivalirudin monotherapyPrimary angioplastyAnticoagulation regimensCardiac eventsCoronary intervention
2002
Overweight and Obesity as Determinants of Cardiovascular Risk: The Framingham Experience
Wilson P, D'Agostino R, Sullivan L, Parise H, Kannel W. Overweight and Obesity as Determinants of Cardiovascular Risk: The Framingham Experience. JAMA Internal Medicine 2002, 162: 1867-1872. PMID: 12196085, DOI: 10.1001/archinte.162.16.1867.Peer-Reviewed Original ResearchConceptsAge-adjusted relative riskBody mass indexCoronary heart diseasePopulation attributable riskRelative riskCardiovascular diseaseCardiovascular sequelaeAngina pectorisExcess weightAttributable riskHeart diseaseOverweight statusRisk factorsCardiovascular disease risk factorsHighest population-attributable riskNew cardiovascular diseaseDisease risk factorsFramingham Heart Study participantsNormal-weight personsDisease end pointsNew hypertensionCardiovascular riskDiabetes mellitusPrimary outcomeMass index